Sponsor

Janssen-Cilag, S.A.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Janssen-Cilag, S.A. appears in 14 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials14
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

14 shown
Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to GolimumabNCT02414984 · lead sponsor · 2015-03-01
TERMINATED
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's DiseaseNCT01181921 · lead sponsor · 2011-05-01
TERMINATED
FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in SpainNCT01376492 · lead sponsor · 2010-11-01
COMPLETED
An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With SchizophreniaNCT01309373 · lead sponsor · 2010-11-01
COMPLETED
A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's DiseaseNCT01478204 · lead sponsor · 2008-06-01
COMPLETED
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With SchizophreniaNCT01724359 · lead sponsor · 2008-02-01
COMPLETED
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With SchizophreniaNCT00358852 · lead sponsor · 2006-08-01
COMPLETED
ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health RegistryNCT00264069 · lead sponsor · 2005-06-01
COMPLETED
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective DisordersNCT00399334 · lead sponsor · 2005-06-01
COMPLETED
A Registry of Treatment Adherence for Patients With SchizophreniaNCT00283517 · lead sponsor · 2003-09-01
COMPLETED
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic PatientsNCT00515489 · lead sponsor · 2001-11-01
TERMINATED
Study on the Safety of Risperidone on Obese or Overweight Patients With SchizophreniaNCT00511628 · lead sponsor · 2001-07-01
TERMINATED
A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)NCT03685500 · collaborator · 2018-12-04
COMPLETED
Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical PracticeNCT03042390 · collaborator · 2016-12-23
COMPLETED

Drugs studied in this sponsor's trials

2 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Janssen-Cilag, S.A. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
risperidone2
galantamine1
risperidone RxCUI 35636 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials galantamine RxCUI 4637 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor12
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.